Peroxisome proliferator-activated receptors (PPARs) were originally identified primarily as regulators of glucose and lipid metabolism. Both PPAR-γ and PPAR-α agonists are widely used clinically for treatment of diabetes and dyslipidemia. More recently, the pivotal role of PPARs in modulating a variety of physiological activities in cell types throughout the body has been recognized. In the lung, they regulate the immune response, inflammation, surfactant production, differentiation, proliferation, and apoptosis of a variety of cells. Even as investigation continues into the fundamental biology of PPARs and the mechanisms through which they act, other studies examine their potential as therapeutic targets. Current progress on both fronts has been and continues to be rapid. We invite authors to contribute review articles describing recent advances in the field as well as original research articles reporting significant new findings. We are interested in articles describing either basic or translational research as well as those illustrating the relationship between the two. Reports of clinical studies are also welcome. Potential topics include, but are not limited to:

• Molecular biology of PPARs
• Signaling pathways controlling PPAR expression or through which PPARs act
• Role of PPARs in specific lung cells (e.g., alveolar macrophages and airway epithelial cells)
• Role of PPARs in physiological processes related to the lung
• Role of PPARs in specific lung diseases (e.g., asthma, fibrosis, and cancer)

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ppar/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: